July 2025 Psychedelic Patent Update Post published:August 22, 2025 Post category:Psychedelic Patent Analysis/Pα+
Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression Post published:August 18, 2025 Post category:Analysis/News/Pα+
One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect Post published:August 15, 2025 Post category:Analysis/Pα+
From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research Post published:August 12, 2025 Post category:Analysis/Interviews
Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions Post published:August 8, 2025 Post category:Psychedelic Bulletin/Pα+
Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches Post published:August 5, 2025 Post category:Analysis/Interviews/News/Pα+
The Psychedelic News Feed: January 5 – June 1, 2025 Post published:August 4, 2025 Post category:Psychedelic News Feed Archive
Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling? Post published:August 1, 2025 Post category:Psychedelic Bulletin/Pα+
Germany Establishes EU’s First Psilocybin Compassionate Access Program Post published:July 31, 2025 Post category:Analysis/News
Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2) Post published:July 29, 2025 Post category:Analysis/News